Investing.com - Financial Markets Worldwide
Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

REFILE-UPDATE 1-Transition Therapeutics' Alzheimer drug effective in sub-group

Published 2015-10-15, 06:50 a/m
REFILE-UPDATE 1-Transition Therapeutics' Alzheimer drug effective in sub-group
TTH
-

(Fixes typo in first paragraph.)
Oct 15 (Reuters) - Drug developer Transition Therapeutics
Inc TTH.TO said its experimental drug reduced severe agitation
and aggression in Alzheimer's patients, citing data from a large
study.
The company said on Thursday that it would use the data to
discuss a potential late-stage trial of the drug, ELND005, with
the U.S. Food and Drug Administration.
The company said in June that the large study did not reduce
moderate-to-severe agitation and aggression, pushing its
U.S.-listed shares down as much as 20 percent that day.
urn:newsml:reuters.com:*:nPn5gKsJL
The latest analysis identified a sub-group within those
patients, who reacted positively to the drug.
ELND005 is the lead experimental drug that Transition
Therapeutics is testing. The Canadian developer has also
completed a mid-stage study of the drug in Down Syndrome
patients.
Transition Therapeutics' U.S.-listed shares closed at $1.93
on Wednesday. The stock has fallen about 20 percent since the
company reported initial results in June.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.